Prestige BioPharma Limited (KRX: 950210)
South Korea
· Delayed Price · Currency is KRW
14,700
-340 (-2.26%)
Dec 20, 2024, 10:52 AM KST
Prestige BioPharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 19, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Market Capitalization | 173,077 | 103,966 | 113,582 | 137,620 | 396,635 | - |
| Market Cap Growth | 38.89% | -8.47% | -17.47% | -65.30% | - | - |
| Enterprise Value | 168,130 | 44,042 | -6,736 | -150,494 | -63,944 | - |
| Last Close Price | 14400.00 | 8650.00 | 9450.00 | 11450.00 | 33000.00 | - |
| PE Ratio | - | - | 6.46 | - | - | - |
| Forward PE | - | 12.01 | 12.01 | 12.01 | - | - |
| PS Ratio | 63.41 | 150.88 | 701.81 | - | - | - |
| PB Ratio | 2.32 | 0.20 | 0.21 | 0.32 | 0.69 | - |
| P/TBV Ratio | 0.53 | 0.26 | 0.28 | 0.32 | 0.69 | - |
| EV/Sales Ratio | 59.13 | 63.91 | - | - | - | - |
| Debt / Equity Ratio | 0.23 | 0.20 | 0.21 | 0.01 | 0.01 | 0.02 |
| Debt / EBITDA Ratio | - | - | 9.11 | - | - | - |
| Asset Turnover | 0.00 | 0.00 | 0.00 | - | - | - |
| Inventory Turnover | 0.09 | 0.10 | 0.01 | - | - | - |
| Quick Ratio | 1.28 | 1.57 | 2.24 | 7.26 | 32.70 | 5.71 |
| Current Ratio | 1.41 | 1.72 | 2.31 | 7.45 | 32.74 | 5.88 |
| Return on Equity (ROE) | -9.51% | -10.38% | -0.59% | -42.08% | -2.07% | - |
| Return on Assets (ROA) | -5.20% | -5.35% | 0.10% | -13.89% | -3.01% | - |
| Return on Capital (ROIC) | -6.18% | -6.07% | 0.12% | -15.08% | -3.18% | - |
| Earnings Yield | -3.41% | -31.67% | 15.47% | -153.65% | -1.86% | - |
| FCF Yield | -48.80% | -65.49% | -95.65% | -74.36% | -4.13% | - |
| Buyback Yield / Dilution | -0.42% | - | - | -16.46% | -20.98% | - |
| Total Shareholder Return | -0.42% | - | - | -16.46% | -20.98% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.